Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

"Erdheim-Chester disease" - Google News
CNS Abnormalities Common in Erdheim-Chester Disease - Neurology Advisor
CNS Abnormalities Common in Erdheim-Chester Disease  Neurology Advisor

Patients with Erdheim-Chester disease (ECD) are at risk for a variety of central nervous system (CNS) abnormalities, and brain and spine magnetic resonance ...


Friday, February 23, 2018 3:00:00 AM

First-Ever FDA Approval for Erdheim-Chester Disease - MedPage Today
First-Ever FDA Approval for Erdheim-Chester Disease  MedPage Today

WASHINGTON -- The FDA today granted a first-ever approval for treatment of the rare blood cancer Erdheim-Chester Disease (ECD), the agency announced.


Monday, November 06, 2017 3:00:00 AM

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation - Rare Disease Report
Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation  Rare Disease Report

The FDA accepted a supplemental New Drug Application and granted Priority Review for Zelboraf, a therapy for Erdheim-Chester disease with a BRAF V600 ...


Sunday, August 06, 2017 3:00:00 AM

Genes associated with Erdheim-Chester disease also linked to cancer - Medical Xpress
Genes associated with Erdheim-Chester disease also linked to cancer  Medical Xpress

National Human Genome Research Institute (NHGRI) researchers have identified new genes associated with the Erdheim-Chester disease (ECD) and some ...


Friday, March 31, 2017 3:00:00 AM

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease - Cancer Network
FDA Approves Vemurafenib for Treating Erdheim-Chester Disease  Cancer Network

The FDA has expanded the approval of vemurafenib (Zelboraf) to include the treatment of Erdheim–Chester disease in adult BRAF V600–positive patients.


Thursday, November 09, 2017 3:00:00 AM

On Rare Disease Day, experts say ‘Don’t give up’ - KING5.com
On Rare Disease Day, experts say ‘Don’t give up’  KING5.com

Rare Disease Day raises awareness of disorders that affect very few of us. A Camano Island woman shares her story of fighting to save her own life.


Wednesday, February 28, 2018 3:00:00 AM

The ultra-rare Erdheim-Chester disease: Turning grief into a campaign for a cure - Washington Post
The ultra-rare Erdheim-Chester disease: Turning grief into a campaign for a cure  Washington Post

Kathy Brewer lost her husband to Erdheim-Chester disease; now she leads global efforts to combat it.


Monday, November 17, 2014 3:00:00 AM

Martin's Lofaro trying to beat rare disease - Jackson Sun
Martin's Lofaro trying to beat rare disease  Jackson Sun

Lofaro is one of three people in Tennessee with ECD. There are 20 in the United States, and 600 in the entire world with the diagnosis.


Tuesday, February 27, 2018 3:00:00 AM

Health: Erdheim-Chester is a rare but deadly disease - 702
Health: Erdheim-Chester is a rare but deadly disease  702

Erdheim-Chester Disease is a rare disease that involves the excessive production of histiocytes, which are a type of white blood cell. This leads to the formation ...


Saturday, April 15, 2017 3:00:00 AM

High Response Rate in Histiocytic Disease With MEK Inhibition - OncLive
High Response Rate in Histiocytic Disease With MEK Inhibition  OncLive

The MEK inhibitor cobimetinib (Cotellic) led to objective responses in 14 of 16 patients with BRAF-mutated and wild-type histiocytic disorders.


Wednesday, January 03, 2018 3:00:00 AM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us 
Follow Me on Pinterest   


¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: outreach@histio.org. Nosotros podremos responderle tan pronto nos sea possible. Gracias!